A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : EMP / estramustine phosphate

[Related PubMed/MEDLINE]
Total Number of Papers: 101
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   EMP  (>> Co-occurring Abbreviation)
Long Form:   estramustine phosphate
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2017 Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution. OS, PCa, RP
2017 [Low-Dose Estramustine Phosphate Monotherapy in Castration-Resistant Prostate Cancer Patients]. CRPC, PSA
2016 Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer. CI, CRPC, PSA
2015 Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer. ASA, CI
2015 Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis. BRFS, LHRH, OS, PCa, RP
2012 Ablation of the ATP-binding cassette transporter, Abca2 modifies response to estrogen-based therapies. ABCA2, KO, WT
2012 Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience. CRPC, DTX, OS, PSA, TTP
2012 Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer. CRPC, PSA, PSADT
2012 Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study. IQR, LHRH, PCa, RP
10  2011 A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. CRPC, IgG, PPV
11  2010 A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. HR, PFS, PPV
12  2010 Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer. LHRH, PSA
13  2010 Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient. HRPC, PSA
14  2010 Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study. ADT
15  2010 Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients. DTX, HRPC, PSA
16  2009 Advantages of second line estramustine for overall survival of hormone-refractory prostate cancer (HRPC) patients. DES, DEX, HRPC
17  2009 Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital. HRPC
18  2008 Comparison of three different chemotherapy regimens containing epirubicin in hormone-refractory prostate cancer patients. HRPC
19  2008 Long-term control or possible cure? Treatment of stage D2 prostate cancer under chemotherapy using cisplatin and estramustine phosphate followed by maximal androgen blockade. PC
20  2008 The effect of combined androgen blockade on bone turnover and bone mineral density in men with prostate cancer. BL, BMD, CAB, OC
21  2008 [Estramustine phosphate withdrawal syndrome in relapsed prostate cancer: two case reports]. BCL, CT, LHRHa, PSA
22  2007 Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. CTL, HRPC, IgG
23  2007 Distribution of radioiodinated estramustine binding protein antibody in mice with DU-145 prostate cancer xenograft. EMBP-AB, RI-EMBP-AB
24  2007 Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer. ---
25  2007 Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. DTX, HRPC
26  2006 A randomized comparative study of endocrine monotherapy and a combination of estramustine phosphate with the endocrine therapy in patients with untreated stage D prostate cancer. PR, PS, PSA
27  2006 Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer. PSA
28  2006 Repeated massive tongue swelling due to the combined use of estramustine phosphate and angiotensin-converting enzyme inhibitor. ACE
29  2005 Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. AIPC, CI
30  2005 Evaluation of lipophilins as determinants of tumor cell response to estramustine. EGFP
31  2005 In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. PDFG-r
32  2005 Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. ---
33  2005 Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer. HRPC, PSA
34  2005 Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. ADT, HRPC, PSA
35  2005 The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate. ---
36  2004 Gene expression profiling reveals novel targets of estramustine phosphate in prostate cancer cells. RT-PCR
37  2004 Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma. AIPC, CI, PSA
38  2004 Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma. NHL
39  2004 Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. VBL
40  2004 Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis. DVT, HRPC, TE
41  2004 [Potentiation of focal ultrasound treatment of prostate adenocarcinoma by concomitant chemotherapy with estramustine phosphate and paclitaxel]. HIFU
42  2003 A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting. DLT, Pacl-E-Vin, PSA
43  2003 Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. i.v
44  2003 Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. ---
45  2003 Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. PSA
46  2002 A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. PSA
47  2002 A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. CI, PSA
48  2002 Chemotherapy for androgen-independent prostate cancer. ---
49  2002 EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer. ---
50  2002 Estramustine phosphate combined with orchidectomy as first-line therapy in patients with prostate carcinoma. Effect of age on survival. ---
51  2002 Estramustine phosphate enhances the effects of hyperthermia and induces the small heat shock protein HSP27 in the human prostate carcinoma cell line PC-3. HSP
52  2002 Ondansetron but not granisetron affect cell volume regulation and potassium ion transport of glioma cells treated with estramustine phosphate. ---
53  2002 Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. AIPC, PSA
54  2002 The flare in alkaline phosphatase activity post-orchidectomy predicts which patient may benefit from early chemotherapy in metastatic prostate cancer. ALP, PFS
55  2002 [Hormonal chemotherapy for hormone-refractory prostate cancer]. CPM, DEX, HRPC, PSA
56  2001 Induction of apoptosis by estramustine phosphate mediated by phosphorylation of bcl-2. ---
57  2001 Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes. ABC, CI
58  2001 The bleb formation of the extracellular pseudopodia; early evidence of microtubule depolymerization by estramustine phosphate in glioma cell; in vitro study. TEM
59  2000 Drug-induced apoptosis by anti-microtubule agent, estramustine phosphate on human malignant glioma cell line, U87MG; in vitro study. TEM
60  2000 Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer. PSA
61  2000 Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme. GBM
62  1999 Serotoninergic modulation of cell volume response to estramustine: an image-analysis study on perifused individual glioma cells. PCA, PCA
63  1998 Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. m-AR, PSA
64  1998 Apoptotic tumor cell death induced by estramustine in patients with malignant glioma. EaM, ISEL
65  1998 Phase I and pharmacologic study of estramustine phosphate and short infusions of paclitaxel in women with solid tumors. ---
66  1997 Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group. ---
67  1997 Computerized detection of morphological changes to glioma cells during estramustine and ion-channel blocker perifusion. PCA
68  1997 Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study. EPR, HRPC, PSA
69  1997 Estramustine-based chemotherapy. ---
70  1997 Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. CR, HRPC, i.v, PRs, PSA
71  1997 Response to estramustine phosphate and paclitaxel in patients with advanced breast cancer: a phase I study. ---
72  1997 Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy. PSA, RT, VBL
73  1996 In vitro inhibition of cell proliferation, viability, and invasiveness in U87MG human glioblastoma cells by estramustine phosphate. ---
74  1995 Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. HRPC
75  1995 Radiosensitizing effect of estramustine in malignant glioma in vitro and in vivo. ---
76  1994 Clinical and biological studies of estramustine phosphate as a novel radiation sensitizer. PSA, RT
77  1994 Cytotoxic effect and uptake of estramustine in a rat glioma model. EaM, EMBP
78  1994 Estramustine potentiates the effects of irradiation on the Dunning (R3327) rat prostatic adenocarcinoma. ---
79  1994 Experience in advanced prostatic cancer: orchiectomy and flutamide versus orchiectomy and estramustine phosphate. ---
80  1994 Expression of estramustine-binding protein in ependymomas and in human and developing rat ependymal cells. EMBP
81  1994 Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies. ChrA, FL, PCNA
82  1994 Prostate specific antigen and prostate acid phosphatase declines after estramustine phosphate withdrawal: a case report. PAP, PSA
83  1993 Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. ---
84  1993 Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumours in humans. EaM, EMBP, EoM
85  1992 Estramustine phosphate and other cytotoxic drugs in the treatment of poor prognostic advanced prostate cancer. ---
86  1992 Estramustine-phosphate binds to a tubulin binding domain on microtubule-associated proteins MAP-2 and tau. ---
87  1992 Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. MR, PR, PSA
88  1991 Early morphological detection of estramustine cytotoxicity measured as alteration in cell size and shape by a new technique of microperifusion. ---
89  1991 Effects of estramustine on DNA and cell membrane in malignant glioma cells. ---
90  1990 Estramustine phosphate in secondary hormone-resistant carcinoma of the prostate. ---
91  1988 Estramustine binding protein and anti-proliferative effect of estramustine in human glioma cell lines. EMBP
92  1988 Estramustine inhibits monocyte phagocytosis. FITC
93  1988 Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer. ---
94  1986 Estramustine phosphate compared with diethylstilbestrol. A randomized, double-blind, crossover trial for stage D prostate cancer. DES
95  1984 Effects of diethylstilbestrol and estramustine phosphate (estracyt) on natural killer cell activity and tumor susceptibility in male mice. DES, NK
96  1984 Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients. ---
97  1983 Suppression of antibody response of male mice exposed to diethylstilbestrol or estramustine phosphate (Estracyt). DES, LPS, SRBC
98  1982 Effect of diethylstilbestrol and estramustine phosphate (Estracyt) on delayed hypersensitivity response to oxazolone in male mice. DES, DTH
99  1982 Effects of diethylstilbestrol and estramustine phosphate (Estracyt) on lymphoid cell populations and mitogen responsiveness in male mice. DES-P
100  1982 In vitro and in vivo effects of diethylstilbestrol and estramustine phosphate (Estracyt) on the mitogen responsiveness of human peripheral blood lymphocytes. DES